How would you advise a patient with well-controlled gastro-oesophageal reflux disease (GORD) who would like to continue their proton pump inhibitor (PPI) therapy?
RACGP for 2 (category 2) points for GPsToggle information
This activity has been accredited for 2 (Category 2) points in the RACGP QI & CPD Program for the 2017 - 2019 triennium (activity number 133040).
ACRRM for 1 Core point for GPsToggle information
This activity has been approved for 1 Core point in the ACRRM PD Program for the 2017 - 2019 triennium (activity code 12954).
- Recognised for the Practice Incentives Program Quality Prescribing Incentive (PIP QPI)
Bill is an active 69-year-old man who would like to continue the pantoprazole that he has been taking for the past 6 months for GORD. What information would you like to know about Bill? How would you respond to his request?
Complete this online case study and receive instant feedback on your responses, compare your approach with your peers and read expert commentary provided by Prof Geoff Hebbard, the Director of Gastroenterology and Hepatology at The Royal Melbourne Hospital.
On completion of this activity you should be able to:
- Apply guideline recommendations for proton pump inhibitor (PPI) use in gastro-oesophageal reflux disease (GORD).
- List rare but serious adverse effects associated with PPI therapy.
- Explain the advantages of and barriers to stepping down and stopping PPI therapy in patients with adequately controlled GORD symptoms.
- Develop a plan when starting treatment for GORD, including lifestyle changes and PPI therapy, with clarity on stepping down and stopping, and review times.
- Discuss and manage expectations when stepping down or stopping PPI therapy, and provide strategies to manage potential rebound acid hypersecretion.